Cargando…

A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care

INTRODUCTION: Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke 4 to 5-fold. The first choice of anticoagulant therapy (AT) is the vitamin K antagonist (VKA). Contraindication to VKA or poor control of the International Normalized Ratio leads to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dalmau Llorca, Maria Rosa, Gonçalves, Alessandra Queiroga, Forcadell Drago, Emma, Fernández-Sáez, José, Hernández Rojas, Zojaina, Pepió Vilaubí, Josep Maria, Rodríguez Cumplido, Dolores, Morral Parente, Rosa Maria, Aguilar Martín, Carina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779750/
https://www.ncbi.nlm.nih.gov/pubmed/29504981
http://dx.doi.org/10.1097/MD.0000000000009578
_version_ 1783294602871046144
author Dalmau Llorca, Maria Rosa
Gonçalves, Alessandra Queiroga
Forcadell Drago, Emma
Fernández-Sáez, José
Hernández Rojas, Zojaina
Pepió Vilaubí, Josep Maria
Rodríguez Cumplido, Dolores
Morral Parente, Rosa Maria
Aguilar Martín, Carina
author_facet Dalmau Llorca, Maria Rosa
Gonçalves, Alessandra Queiroga
Forcadell Drago, Emma
Fernández-Sáez, José
Hernández Rojas, Zojaina
Pepió Vilaubí, Josep Maria
Rodríguez Cumplido, Dolores
Morral Parente, Rosa Maria
Aguilar Martín, Carina
author_sort Dalmau Llorca, Maria Rosa
collection PubMed
description INTRODUCTION: Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke 4 to 5-fold. The first choice of anticoagulant therapy (AT) is the vitamin K antagonist (VKA). Contraindication to VKA or poor control of the International Normalized Ratio leads to the administration of direct-acting oral anticoagulants. There is a trend toward inadequate AT in nonvalvular AF (NVAF) patients. Aim: To evaluate the impact of the implementation of a decision support tool linked to the digital clinical history on the adequacy of AT, the incidence of complications, and the mortality in patients with NVAF in primary care centers (PCCs) of the Catalan Institute of Health (ICS). METHODS AND ANALYSIS: Randomized clinical trial in 287 PCCs, formed by 2 groups (intervention and control). Population: patients controlled in PCCs, diagnosed with NVAF 1 year before the implementation of the decision support tool and with VKA treatment over a minimum of 1 year. A simple randomization method will be performed at a sector level. The decision support tool will be available for 1 year. The time in therapeutic range (TTR) will be available in the digital clinical history only to professionals of the intervention group. The information system for primary care research development database will be used for the data extraction. Statistical analysis will be done at 3 time points: before the implementation of the tool, at 1 year, and at 2 years after the beginning of the intervention. Multilevel (patient and professional levels) logistic regression models will be used to estimate the effect of the intervention. ETHICS AND DISSEMINATION: This study protocol was approved by the Ethical Committee of Clinical Investigation of the Institut Universitari d’Investigació en Atenció Primària Jordi Gol (code P17/091). Articles will be published in scientific journals. TRIAL REGISTRATION: Clinical-Trials.gov: NCT03367325.
format Online
Article
Text
id pubmed-5779750
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-57797502018-02-05 A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care Dalmau Llorca, Maria Rosa Gonçalves, Alessandra Queiroga Forcadell Drago, Emma Fernández-Sáez, José Hernández Rojas, Zojaina Pepió Vilaubí, Josep Maria Rodríguez Cumplido, Dolores Morral Parente, Rosa Maria Aguilar Martín, Carina Medicine (Baltimore) 6400 INTRODUCTION: Atrial fibrillation (AF) is the most common cardiac arrhythmia and increases the risk of ischemic stroke 4 to 5-fold. The first choice of anticoagulant therapy (AT) is the vitamin K antagonist (VKA). Contraindication to VKA or poor control of the International Normalized Ratio leads to the administration of direct-acting oral anticoagulants. There is a trend toward inadequate AT in nonvalvular AF (NVAF) patients. Aim: To evaluate the impact of the implementation of a decision support tool linked to the digital clinical history on the adequacy of AT, the incidence of complications, and the mortality in patients with NVAF in primary care centers (PCCs) of the Catalan Institute of Health (ICS). METHODS AND ANALYSIS: Randomized clinical trial in 287 PCCs, formed by 2 groups (intervention and control). Population: patients controlled in PCCs, diagnosed with NVAF 1 year before the implementation of the decision support tool and with VKA treatment over a minimum of 1 year. A simple randomization method will be performed at a sector level. The decision support tool will be available for 1 year. The time in therapeutic range (TTR) will be available in the digital clinical history only to professionals of the intervention group. The information system for primary care research development database will be used for the data extraction. Statistical analysis will be done at 3 time points: before the implementation of the tool, at 1 year, and at 2 years after the beginning of the intervention. Multilevel (patient and professional levels) logistic regression models will be used to estimate the effect of the intervention. ETHICS AND DISSEMINATION: This study protocol was approved by the Ethical Committee of Clinical Investigation of the Institut Universitari d’Investigació en Atenció Primària Jordi Gol (code P17/091). Articles will be published in scientific journals. TRIAL REGISTRATION: Clinical-Trials.gov: NCT03367325. Wolters Kluwer Health 2018-01-19 /pmc/articles/PMC5779750/ /pubmed/29504981 http://dx.doi.org/10.1097/MD.0000000000009578 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 6400
Dalmau Llorca, Maria Rosa
Gonçalves, Alessandra Queiroga
Forcadell Drago, Emma
Fernández-Sáez, José
Hernández Rojas, Zojaina
Pepió Vilaubí, Josep Maria
Rodríguez Cumplido, Dolores
Morral Parente, Rosa Maria
Aguilar Martín, Carina
A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care
title A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care
title_full A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care
title_fullStr A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care
title_full_unstemmed A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care
title_short A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care
title_sort new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: a randomized clinical trial in primary care
topic 6400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5779750/
https://www.ncbi.nlm.nih.gov/pubmed/29504981
http://dx.doi.org/10.1097/MD.0000000000009578
work_keys_str_mv AT dalmaullorcamariarosa anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT goncalvesalessandraqueiroga anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT forcadelldragoemma anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT fernandezsaezjose anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT hernandezrojaszojaina anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT pepiovilaubijosepmaria anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT rodriguezcumplidodolores anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT morralparenterosamaria anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT aguilarmartincarina anewclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT dalmaullorcamariarosa newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT goncalvesalessandraqueiroga newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT forcadelldragoemma newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT fernandezsaezjose newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT hernandezrojaszojaina newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT pepiovilaubijosepmaria newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT rodriguezcumplidodolores newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT morralparenterosamaria newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare
AT aguilarmartincarina newclinicaldecisionsupporttoolforimprovingtheadequacyofanticoagulanttherapyandreducingtheincidenceofstrokeinnonvalvularatrialfibrillationarandomizedclinicaltrialinprimarycare